real peptides FAQ

Review your administration timing first. Doses taken outside cortisol peak windows produce minimal effect regardless of amount. Verify you're dosing within 60 minutes post-waking and again between 2–4 PM. If timing is correct, escalate from 300 mcg BID to 300 mcg TID (900 mcg daily total) for an additional 7 days. Non-responders at 900 mcg daily after 3 weeks may have COMT or MAO-A polymorphisms that limit Selank efficacy. Consider alternative anxiolytic peptides like P21 which operates through different neurochemical pathways.

Discard it immediately. Do not inject. Properly reconstituted survodutide is clear and colorless. Cloudiness, particulates, or discoloration indicate protein aggregation or contamination. This occurs when bacteriostatic water is injected too forcefully, when the vial is shaken instead of swirled, or when the lyophilized powder was exposed to temperature extremes before reconstitution. Use a new vial and verify storage conditions. Cloudy peptide solutions cannot be filtered or salvaged. The denatured protein structure is permanent.

Unreconstituted lyophilized survodutide tolerates up to 48 hours at 25°C without significant potency loss. Return it to −20°C immediately. Reconstituted solution exposed to room temperature for more than 8 hours should be discarded. The 6.5-day half-life creates a therapeutic buffer. A single missed dose won't eliminate plasma levels entirely, but using degraded product introduces dosing inconsistency that compromises study validity. For transport, use insulin coolers that maintain 2–8°C for 36–48 hours without ice or electricity.

Order IGF-1 bloodwork immediately. If IGF-1 hasn't increased by at least 40 ng/mL from baseline, the issue is either product quality (degraded peptide, incorrect dosing), administration error (injecting too soon after eating, inconsistent timing), or pituitary hyporesponsiveness. Verify reconstitution math. A common mistake is miscalculating concentration, leading to underdosing by 30–50%. If IGF-1 did increase appropriately but you feel no subjective improvement, the issue may be unrelated to GH. Chronic stress elevating cortisol, thyroid dysfunction (TSH >2.5 mIU/L), or iron deficiency (ferritin <50 ng/mL) all blunt perceived energy despite adequate GH levels.

Check your energy balance first. Ipamorelin optimises substrate utilisation but doesn't override thermodynamics. If you're in caloric surplus, the free fatty acids released through HSL activation get re-esterified and stored. GH elevation shifts fuel preference toward fat oxidation, but fat oxidation only produces net fat loss when total energy expenditure exceeds intake. The second variable: injection timing. Dosing too close to meals, inconsistent administration times, or inadequate dose spacing can produce suboptimal GH pulses that don't sustain lipolytic signalling long enough to matter.

Transient sleep disruption during days 3–7 is reported in approximately 15–20% of users and likely reflects circadian rhythm recalibration as endogenous melatonin timing shifts. This resolves spontaneously by day 8–10 in nearly all cases. If severe insomnia persists beyond day 10, discontinue and consult a healthcare provider. This suggests an unrelated sleep pathology that Epithalon cannot address.

Stop immediately and you lose 60–80% of potential structural benefit. Symptom relief at week 6 comes from reduced synovial inflammation, not completed cartilage repair. Collagen fibers deposited by week 6 haven't cross-linked yet. They're structurally weak and reabsorb within 4–6 weeks without continued IGF-1 stimulation. A 2020 study tracking premature discontinuation found that patients who stopped at week 6 returned to baseline joint pain scores by week 14, while those who completed 16 weeks maintained 70% of pain reduction at 6-month follow-up.

Unreconstituted lyophilized sermorelin can tolerate ambient temperature (up to 25°C) for 24–48 hours without significant degradation. Reconstituted sermorelin is far more fragile. A single overnight exposure to room temperature (20–22°C) causes approximately 15–25% potency loss, and exposure above 25°C accelerates degradation exponentially. If the vial was out for fewer than 8 hours at room temperature, you can likely continue using it but should expect reduced efficacy. Beyond 12 hours or if room temperature exceeded 25°C, discard the vial. Partially degraded peptide still binds to receptors but produces blunted GH response, making it impossible to dose accurately.

Skip the dose escalation entirely and maintain your starting dose for two full weeks. Early satiety (phase 1) is gastric, not central. Some subjects have naturally faster gastric emptying rates and won't feel the pyloric effect until amylin receptor density increases in phase 2. If no appetite change occurs by week 3, the issue is likely receptor variant expression (AMY3 polymorphism reduces binding affinity in 8–12% of populations). Dose increase won't fix a receptor binding issue. Mechanism verification through comparative GLP-1 response is the next diagnostic step.

Administer the next scheduled dose as planned. Do not attempt a 'makeup' injection. The glucose-induced GH suppression from the mistimed dose will resolve within 2–3 hours as blood sugar returns to baseline. Doubling the next dose to compensate creates a high-amplitude GH pulse on top of residual insulin elevation, which can trigger reactive hypoglycemia 90–120 minutes post-injection. The single missed pulse has negligible impact on cumulative weekly GH exposure. Consistency across 15–20 properly timed injections matters far more than one lost dose.

Verify peptide purity and storage integrity. Degraded or improperly stored ipamorelin loses receptor affinity. Lyophilised peptides exposed to temperatures above 25°C for extended periods or reconstituted solutions stored beyond 28 days undergo peptide bond hydrolysis that reduces biological activity without visible changes in appearance. The second possibility: receptor desensitisation from continuous use without cycling. GHS-R1a receptors downregulate when constantly activated. Taking 4–7 day breaks every 8–12 weeks restores receptor density and responsiveness.

Take the missed dose as soon as you remember if it's within 3 hours of the scheduled time. Beyond that window, skip it and resume your regular schedule. Doubling the next dose to 'catch up' doesn't increase efficacy and may cause transient hypotension (Selank dilates peripheral vasculature at high acute doses). The peptide's 25-minute half-life means plasma levels return to baseline within 2–3 hours, so missing one dose won't disrupt long-term therapeutic response as long as you maintain the overall twice-daily rhythm.

Discard the vial immediately. Cloudiness indicates bacterial contamination or protein aggregation. Both compromise bioavailability and introduce variables that invalidate research outcomes. Particulates suggest improper reconstitution technique (shaking instead of swirling) or contamination from the rubber stopper. LIPO-C B12 should remain clear to pale yellow post-reconstitution. If cloudiness appears within 48 hours, the bacteriostatic water itself may be contaminated. Verify water sterility before reconstituting another vial.

If the peptide was still lyophilised (freeze-dried powder), a single 12–16 hour ambient temperature exposure (up to 25°C) typically doesn't cause complete degradation. Though potency may drop 10–20%. If already reconstituted with bacteriostatic water, prolonged exposure above 8°C breaks peptide bonds irreversibly. You can't visually confirm potency loss. Degraded GHRP-6 looks identical to active peptide. Research facilities discard any reconstituted vial exposed to temperatures outside the 2–8°C range for more than 2 hours.

Telomerase reactivation in normal somatic cells is mechanistically distinct from the constitutive telomerase expression seen in 85–90% of human cancers. Cancer cells bypass normal growth controls and express telomerase continuously to sustain unlimited replication. Epithalon causes transient, regulated telomerase activation that doesn't override cellular checkpoints like p53 or RB. No epithalon trial has reported increased cancer incidence, but the theoretical risk isn't zero. If you have active malignancy, personal history of cancer, or strong family history (especially BRCA mutations), avoid telomerase activators until more long-term safety data exists. Senolytic protocols (which clear pre-cancerous senescent cells) may be a safer longevity approach in high-risk populations.

If you miss 1–2 days during a 10-day cycle, continue from where you left off and extend the cycle by the number of missed days. Complete all 10 injections. If you miss 3+ consecutive days, the epigenetic signalling cascade may reset, reducing efficacy. In that case, stop the current cycle, wait 4–6 weeks, and restart a fresh 10-day protocol. Don't attempt to 'catch up' by doubling doses. Higher single doses don't increase telomerase activation and may increase injection site reactions. Consistency matters more than perfection: 8–9 injections completed on schedule outperform a fragmented 10-day cycle with multiple gaps.

Resume dosing immediately without attempting to 'catch up' by doubling doses. Missing 3 days between Days 7–21 does not reset BDNF upregulation to baseline, but it does slow the rate of synaptic remodelling. Extend the protocol by 5–7 days beyond Day 21 to compensate for the missed window. Gaps longer than 5 days during the neuroplastic phase typically require restarting the 21-day timeline from Day 1.

Administer the missed dose as soon as you remember, provided fewer than 6 hours remain until the next scheduled dose. If more than 6 hours have passed, skip the missed dose and resume your regular schedule. Do not double-dose to compensate. NNMT inhibition relies on sustained presence, not peak concentration; doubling a dose creates unnecessarily high plasma levels without improving enzyme suppression and may increase methylation pathway stress as SAM consumption spikes.

This is not tolerance. It is the transition point between acute pharmacological response and delayed neuroplastic adaptation. Continue dosing through Day 21 without increasing dose. The BDNF-driven structural changes require 14+ days to manifest, and most users report a 'second wave' of anxiety reduction around Day 12–14 as dendritic remodelling begins. Stopping at Day 10 because the acute effect feels diminished is the most common protocol failure.

GHRP-6 acetate isn't designed for sustained appetite elevation. Repeat dosing is the standard approach. Administering a second dose 90–120 minutes after the first re-initiates the appetite window without causing receptor desensitisation in short-term protocols. For multi-day or chronic studies, administer GHRP-6 acetate 20–30 minutes before each scheduled feeding rather than attempting continuous coverage. Continuous infusion models require 3–5× higher total daily doses and introduce tachyphylaxis risks that pulsed dosing avoids.